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Abstract
Background: Asthma leads to structural changes in the airways, including the modification of extracellular matrix
proteins such as tenascin-C. The role of tenascin-C is unclear, but it might act as an early initiator of airway wall
remodelling, as its expression is increased in the mouse and human airways during allergic inflammation. In this
study, we examined whether Th1 or Th2 cells are important regulators of tenascin-C in experimental allergic
asthma utilizing mice with impaired Th1 (STAT4-/-) or Th2 (STAT6-/-) immunity.
Methods: Balb/c wildtype (WT), STAT4-/- and STAT6-/- mice were sensitized with intraperitoneally injected
ovalbumin (OVA) followed by OVA or PBS airway challenge. Airway hyperreactivity (AHR) was measured and
samples were collected. Real time PCR and immunohistochemistry were used to study cytokines and differences in
the expression of tenascin-C. Tenascin-C expression was measured in human fibroblasts after treatment with TNF-a
and IFN-g in vitro.
Results: OVA-challenged WT mice showed allergic inflammation and AHR in the airways along with increased
expression of TNF-a, IFN-g, IL-4 and tenascin-C in the lungs. OVA-challenged STAT4-/- mice exhibited elevated AHR
and pulmonary eosinophilia. The mRNA expression of TNF-a and IFN-g was low, but the expression of IL-4 was
significantly elevated in these mice. OVA-challenged STAT6-/- mice had neither AHR nor pulmonary eosinophilia,
but had increased expression of mRNA for TNF-a, IFN-g and IL-4. The expression of tenascin-C in the lungs of OVA-
challenged STAT4-/- mice was weaker than in those of OVA-challenged WT and STAT6-/- mice suggesting that
TNF-a and IFN-g may regulate tenascin-C expression in vivo. The stimulation of human fibroblasts with TNF-a and
IFN-g induced the expression of tenascin-C confirming our in vivo findings.
Conclusions: Expression of tenascin-C is significantly attenuated in the airways of STAT4-/- mice, which may be
due to the impaired secretion of TNF-a and IFN-g in these mice.
Background
Allergic asthma is an inflammatory disorder of the air-
ways characterised by episodes of airway obstruction
and wheezing. Th2 cells secreting IL-4, IL-5 and IL-13
have been identified in the airways of asthmatic patients.
In humans, Th2 cytokines produced in the respiratory
tract lead to airway eosinophilia, high levels of serum
IgE, and mast cell activation [1], which are believed to
contribute to pathologies such as airway hyperrespon-
siveness (AHR), epithelial damage and mucus secretion.
Accumulating evidence suggests, however, that airway
inflammation alone may not explain the irreversible pro-
gression of the disease in some patients despite anti-
inflammatory therapy [2]. Therefore, in recent years,
greater effort has focused on remodelling of the airways,
which entails thickening of the airway wall, depositing
extracellular matrix (ECM) proteins, and altering their
epithelial composition [1].
The expression of tenascin-C is increased in the air-
way wall in asthma. Tenascin-C belongs to the matricel-
lular proteins and is widely expressed during embryonic
development, but is generally lacking in adult tissues.
Tenascin-C contributes to cell adhesion, migration and
proliferation [3], participates in lung development and
remodelling [3,4], and is necessary for branching mor-
phogenesis of the bronchial tree [4,5]. Tenascin-C is
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expression is sparse or absent under the bronchial
epithelium in healthy adults [8]. We have previously
demonstrated that human patients with asthma show
elevated levels of tenascin-C in the BM of the bronchi
quite early after diagnosis [8,9]. However, very little is
known about the regulation of tenascin-C or its role in
asthma in vivo.
S T A T 6a n dS T A T 4a r em e m b e r so ft h es i g n a lt r a n s -
ducer and activator of transcription (STAT) family of
transcription factors. STAT6 is critical in mediating the
effects of IL-4 and IL-13 [10,11]. Thus, STAT6 is impor-
tant in Th2 lymphocyte differentiation, allergic
responses such as AHR, and combating parasitic infec-
tions in mice. STAT6 induces the expression of IL-4
and down-regulates the production of IFN-g [12].
STAT6 has been suggested as a possible new target for
asthma treatment [13,14]. STAT4, on the other hand,
mediates the effects of IL-12 on gene transcription,
thereby promoting Th1 lymphocyte differentiation, and
IFN-g is one of its main targets [12,15]. Interestingly,
STAT4 seems to also play an important role in Th2
responses [16,17].
We investigated whether one of these two distinct
parts of adaptive immunity, Th1 or Th2, might play an
independent role in the regulation of tenascin-C expres-
sion in experimental allergic asthma in the lung. We
explored the contribution of impairment in Th1 and
Th2 immunity to tenascin-C expression using STAT4-/-
and STAT6 -/- mice. Furthermore, we examined the
expression of Th1 (IFN-g) cytokines, Th2 (IL-4) cyto-
kines and TNF-a, which are all important in asthma [1]
and are possible regulators of tenascin-C expression
[9,18-21]. The results were tested and confirmed with
human cells in vitro.
Methods
Animals
BALB/c female mice, age 6 to10 weeks and free of spe-
cific pathogens, were obtained from M&B, Denmark.
STAT4-/- and STAT6-/- mice, both of Balb/c back-
ground, were purchased from Jackson Laboratory (Bar
Harbor, Maine, USA). All the mice were housed under
specific pathogen-free conditions and maintained on an
ovalbumin-free diet at the Finnish Occupational Health
Institute. All the experiments were approved by the
State Provincial Office of Southern Finland.
Sensitisation and airway challenge
On days 0 and 14, all mice were sensitised with an
intraperitoneal (i.p) injection of 50 μg of ovalbumin
(OVA) (Grade V; Sigma, St. Louis, MO, USA) emulsified
in 2 mg of aluminium hydroxide in a total volume of
100 μl. The mice were intranasally challenged with 50 μl
of PBS (controls) or with 50 μg of OVA diluted in 50 μl
of PBS for three days (days 28, 29 and 30) under isoflur-
ane anaesthesia with spontaneous breathing. Eight mice
were assigned to each group.
Determination of airway responsiveness
Airway responsiveness was assessed 24 hours after the
last OVA airway challenge. A single-chamber whole-
body plethysmograph system obtained from Buxco
Technologies (Troy, NY, USA) was used as described
[22]. Briefly, mice were placed unrestrained into a cham-
ber and exposed for five min to nebulised PBS and sub-
sequently to increasing concentrations of methacholine
(MCh) (Sigma-Aldrich, UK) in PBS using an AeroSonic
5000 D ultrasonic nebuliser (DeVilbiss, Somerset, PA).
Recordings were taken after each nebulisation for five
min. The enhanced pause (Penh) values for each five-
min sequence were evaluated and expressed for each
MCh concentration. Baseline Penh values did not differ
significantly between groups.
Sample collections and lung preparations
The mice were killed by isoflurane overdose and the
blood was drained from the hepatic vein. The chest cav-
ity was opened, and the lungs were lavaged with 800 μl
of PBS via the tracheal tube. The bronchoalveolar lavage
(BAL) sample was cytospun on a slide, the cells were
stained with MayGrünwald-Giemsa (MGG) stain, and
the cell differentials were counted under a light micro-
scope. The left lung was removed, quick-frozen and
stored at -70°C for RNA isolation. For the immunohisto-
logical examination, half of the right lung was embedded
in TissueTek OCT Compound (Sakura Finetek Europe
B.V., The Netherlands), quick-frozen and stored at
-70°C. The other half was fixed in paraformaldehyde
and embedded in paraffin.
Real-time quantitative RT-PCR assay
Total RNA from the lungs and cells was extracted using
Eurozol Reagent (EuroClone, Italy) according to the
manufacturer’s instructions. Total RNA was quantified
with spectrophotometry (Nanodrop, Nanodrop Technol-
ogies, Wilmington, DE, USA). The RNA was reverse-
transcribed into cDNA with a High Capacity cDNA
Reverse Transcription Kit (Applied Biosytems, Foster
City, CA, USA). The real-time quantitative polymerase
chain reaction (PCR) was performed with an Applied
Biosystems 7500 Fast Real-Time PCR System, according
to the manufacturer’s instructions. PCR primers and
probes were obtained as predeveloped assay reagents
(cytokines and 18 S rRNA) or were generated (tenascin-C)
with PrimerExpress version 1.5 software and ordered from
Applied Biosystems. The primer and probe sequences for
tenascin-C were as follows: forward primer 5’-ACC ATG
Meuronen et al. Respiratory Research 2011, 12:2
http://respiratory-research.com/content/12/1/2
Page 2 of 9CTG AGA TAG ATG TTC CAA A-3’, reverse primer 5’-
CTT GAC AGC AGA AAC ACC AAT CC-3’, and probe
5’-ACC ACA CTC ACA GGT CTA AGG CCC GG-3’.
The accumulation of PCR products was detected directly
by monitoring the increase in fluorescence of the reporter
dye. The signals were standardised to the internal passive
reference ROX to exclude non-PCR-related fluctuations in
the fluorescence. In addition, FAM signals were standar-
dised to the endogenous reference rRNA 18S to normalise
the quantification of mRNA targets for differences in total
RNA.
Immunohistochemistry
Quick-frozen samples were used for immunofluore-
sence. Monoclonal rat anti-mouse antibody clone
MTn-12 from Sigma-Aldrich (1:200) served to detect
tenascin-C and fluorescein (FITC)-conjugated anti-rat
IgG (Jackson ImmunoResearch Laboratories Europe,
UK) (1:100) served as a secondary antibody. The inten-
sity of immunoreactivity for tenascin-C was graded in
random order slide by slide. All the groups were graded
at the same time. This resulted in grades from 0-4
(0 = no reactivity, 1 = weak reactivity, 2 = intermediate
reactivity, 3 = strong reactivity, 4 = very strong reactiv-
ity). All samples were coded, and the codes were broken
after completion of all the tests.
Cells
MRC-9 cells were obtained from ATCC (Manassas, VA,
USA). The cells were cultured in MEM supplemented
with 10% FBS, 2 mM glutamine, 0.1 mM nonessential
amino acids, 1.5 g/L of sodium pyruvate and antibiotics
(Gibco, Invitrogen, Life Technologies, Carlsbad, CA,
USA) at 37°C in 5% CO2. Cells were stimulated with
TNF-a (10 ng/ml) (Biosource International, Camarillo,
CA, USA) at 37°C for three and nine hours.
Primary human dermal fibroblasts isolated from adult
skin were purchased from Gibco and cultured in Med-
ium 106 (Gibco) supplemented with LSGS (Low serum
growth supplement) and antibiotics (Gibco) at 37°C in
5% CO2. Cells were stimulated with TNF-a (20 ng/ml),
IFN-g (500 IU/ml, Immuno Tools, Friesoythe, Germany)
and with a combination of TNF-a and IFN-g for 2, 6
and 18 hours.
Western blotting
Tenascin-C protein was analyzed by Western blot from
whole-cell extracts and concentrated cell supernatants.
Human primary fibroblasts stimulated with the combi-
nation of TNF-a and IFN-g for 18 h were lysed in
protein lysis buffer containing 10 mM Tris (pH7.4),
150 mM NaCl, and 25% ethylene glycol supplemented
with complete mini protease inhibitor mixture (Roche
Diagnostic, Indianapolis, IN). The cell extract was
homogenized with ultrasound sonicator (Sanyo Electro-
nics, San Diego, CA). Total protein concentrations were
determined with Bio-Rad DcP r o t e i nA s s a y( B i o - R a d
Laboratories, Hercules, CA) according to the manufac-
turer’s instructions. 20 μg of protein from lysed cell
extracts and 7,5 μl of concentrated cell culture superna-
tants were separated with SDS-PAGE on 12% gels and
transferred onto Immobilon-P Transfer Membranes
(Millipore). Membranes were blocked with 5% non-fat
milk in PBS and exposed to monoclonal mouse antihu-
man antibody 100EB2 recognizing tenascin-C [23]. After
this, membrane was incubated with HRP-conjugated
polyclonal goat anti-mouse immunoglobulins (Dako
Cytomation). Proteins were visualized by Luminescent
Image Analyzer (Image Quant LAS4000mini, GE
Healthcare, Sweden). Total protein in the membrane
was stained with SYPRO Ruby Protein Blot Stain (Bio-
Rad Laboratories).
Statistical Analysis
T h ed a t aw e r ea n a l y s e dw i t hG r a p h P a d P r i s mS o f t w a r e
(GraphPad Software, Inc., CA, USA). Single-group com-
parisons were performed with the Mann-Whitney U-test
or Student’s t-test when appropriate. Values for mea-
surements are expressed as the mean ± the standard
error of the mean (SEM). P values < 0.05 were consid-
ered significant.
Results
Tenascin-C levels are significantly elevated in the airways
of ovalbumin-sensitised and challenged mice
A significant and prominent influx of eosinophils, lym-
phocytes and neutrophils in BAL was observable in
OVA-challenged WT mice, whereas no eosinophils and
only a few lymphocytes and neutrophils appeared in the
BAL of the control mice (Figure 1A). Bronchial reactivity
to inhaled methacholine was significantly higher in the
OVA-challenged mice than in the controls (Figure 1B).
The mRNA levels of proinflammatory cytokine TNF-a,
Th2 cytokine IL-4 and Th1 cytokine IFN-g were signifi-
cantly higher in the lung tissue of the OVA-challenged
WT mice (Figure 1C). All these results indicate that our
mouse model presents an acute allergic asthmatic
response in the airways.
Tenascin-C mRNA levels were significantly higher in
the lung tissue of the OVA-challenged WT mice than in
that of the PBS-challenged mice (Figure 2A). Tenascin-C
immunoreactivity was weak and sparse in the control
mice, although some staining was occasionally detected
in the bronchial veins, the basal layer of the epithelium,
and the smooth muscle beneath the bronchial epithelium
(Figure 2B). In the OVA-challenged WT mice,
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Figure 1 BAL (bronchoalveolar lavage) fluid cell counts, airway hyperreactivity and the mRNA expression of cytokines in ovalbumin
(OVA)-challenged wildtype Balb/c mice compared to PBS-challenged controls. A. Absolute number of eosinophils, lymphocytes,
macrophages and neutrophils in BAL fluid. B. Bronchial hyperreactivity expressed as enhanced-pause values (Penh) for each concentration of
methacholine. C. Relative mRNA expression of pro-inflammatory cytokines TNF-a, Th2 cytokine IL-4 and Th1 cytokine IFN-g compared to controls.
RU = relative expression unit. Results are expressed as mean ± SEM. * p < 0.05, **p < 0.01, ***p < 0.001. n = 8 mice/group.
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regulated in the alveolar structures and was evident in
small spots throughout the parenchyma (Figure 2C). The
larger veins were extremely immunoreactive in places in
the WT mice (not shown), whereas immunoreactivity for
tenascin-C in the bronchial BM was negative in all
groups.
Tenascin-C levels are significantly reduced in OVA-
challenged STAT4-/- mice but normal in STAT6-/- mice
The number of BAL eosinophils was significantly higher
in the OVA-challenged STAT4-/- mice than in the PBS-
challenged controls, with only a minor significant
increase in the number of lymphocytes and neutrophils.
There was also a minor significant decrease in the num-
ber of macrophages (Figure 3A). In contrast, an increase
in the number of airway lumen eosinophils was minimal
in the OVA-challenged STAT6-/- mice, but the influx of
lymphocytes was comparable to that in the WT mice
(Figure 3B). The number of neutrophils also was
increased. Airway reactivity to methacholine was signifi-
cantly stronger in the OVA-challenged STAT4-/- mice
than in the PBS-challenged controls (Figure 3C). Com-
pared to the PBS-challenged controls, the OVA-
challenged STAT6-/- mice showed no airway hyperreac-
tivity (Figure 3D). The expression of mRNA for major
Th2 cytokine IL-4 was significantly elevated in the lung
tissue of the OVA-challenged STAT4-/- mice, but we
found no significant induction of proinflammatory cyto-
kine TNF-a or Th1 cytokine IFN-g (Figure 4). The mRNA
expression of TNF-a,I F N - g and IL-4, however, was signif-
icantly higher in the OVA-challenged STAT6-/- mice
than in the PBS-challenged controls (Figure 4).
The expression of tenascin-C mRNA in the lung tissue
of the OVA-challenged STAT4-/- mice remained
unchanged and was comparable to that of the control
mice (Figure 5A). In contrast, the expression of tenas-
cin-C was significantly higher in the OVA-challenged
than in the PBS-challenged STAT6-/- mice (Figure 5A).
In lung sections, tenascin-C immunoreactivity was nega-
tive in the PBS-challenged STAT4-/- and STAT6-/-
mice (Figure 5B and 5C respectively). The OVA-chal-
lenged STAT4-/- mice (Figure 5D) showed weaker
immunoreactivity to tenascin-C than did their WT
(Figure 2C) and STAT6-/- counterparts (Figure 5E). The
localisation of immunoreactivity was quite similar in all
the groups except that STAT4-/- and STAT6-/- mice
had no OVA-induced tenascin-C expression in the veins
as the WT mice did. Immunoreactivity to tenascin-C
was strongly up-regulated in the alveolar structures and
was found in small spots throughout the parenchyma of
the OVA-challenged mice in the STAT6-/- group, cor-
responding to that of the WT mice. Semi-quantitative
analysis of immunoreactivity for tenascin-C in the lung
biopsies also showed diminished induction of tenascin-C
expression by ovalbumin in STAT4-/- mice compared
to WT and STAT6-/- mice (Figure 5F).
TNF-a stimulation triggers enhanced levels of tenascin-C
from the cultured human lung fibroblasts
Our in vivo studies showed that tenascin-C expression was
severely blunted in the airways of the OVA-challenged
STAT4-/- mice. Moreover, the expression of major proin-
flammatory cytokine TNF-a was impaired in the lung tis-
sue of the STAT4-/- mice. We therefore anticipated that
impaired tenascin-C expression might stem from a lack of
TNF-a stimulation in the airways of the OVA-challenged
STAT4-/- mice. Indeed, the elevated expression of tenas-
cin-C mRNA was evident in human lung fibroblasts
(MRC-9) after stimulation with recombinant TNF-a
(Figure 6A). This TNF-a-induced expression was time-
dependent, peaking at 9 h.
In order to show that this increase in tenascin-C
expression is not an MRC-9-specific phenomenon, we
performed similar stimulations with human primary
fibroblasts in which TNF-a also enhanced the
expression of tenascin-C mRNA (Figure 6B). When the
primary cells were culture di nt h ep r e s e n c eo fT N F - a
and with the major Th1 cytokine, IFN-g, the expres-
sion of tenascin-C mRNA appeared to increase in a
cumulative manner (Figure 6B ) .F u r t h e r ,t h ep r o t e i n
Tenascin-C mRNA
PBS OVA
0
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Figure 2 Tenascin-C expression in wildtype mice. A. The relative
mRNA expression of tenascin-C in the lung of ovalbumin-
challenged and control mice. B-C. Immunofluoresence. The
immunoreactivity of tenascin-C in the lungs of control (B) and
ovalbumin-challenged mice (C). The lung parenchyma was stained
brightly with tenascin-C in the ovalbumin-challenged mice, but not
in the control mice. All the mice showed sparse and faint
immunoreactivity to tenascin-C in the veins and bronchial smooth
muscle. The bronchial basement membrane tested negative for
tenascin-C in both groups. RU = relative expression unit. Results are
expressed mean ± SEM. ** p < 0.01, *** p < 0.001. n = 8 mice/
group.
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Page 5 of 9expression for tenascin-C was also elevated after the
stimulation with TNF-a and IFN-g for 18 h in the
human primary fibroblasts as well as in the culture
supernatant (Figure 6C).
Discussion
Previous studies have demonstrated that prolonged
allergic asthma may lead to structural changes in the
airways, which include the modification of extracellular
matrix proteins such as tenascin-C. In the present study
we investigated the contribution of major Th1 and Th2
transcription factors (i.e. STAT4 and STAT6) to
the regulation of expression profiles of tenascin-C in
the asthmatic airways of mice. We found similar up-
regulation of tenascin mRNA and protein in the OVA-
challenged WT and STAT6-/- mice. Surprisingly,
however, the OVA-challenged STAT4-/- mice showed
no increase in tenascin-C mRNA production after aller-
gen challenge, suggesting that STAT4 is an important
regulator of tenascin-C in acute allergic asthma.
Tenascin-C is expressed both pre- and postnatally in
the developing lung [5-7] and is thought to be involved
in various inflammatory and fibrotic processes in the
adult lung [3]. However, the exact mechanisms are still
unknown. In the healthy adult human and mouse lung,
tenascin-C is usually absent or its expression is sparse
[5-8]. A coding single nucleotide polymorphism (SNP)
in the tenascin-C gene has been linked to asthma in
adulthood in the Japanese population [24]. In addition,
cyclic strain, which is seen during bronchoconstriction,
induces tenascin-C production through changes in the
actin cytoskeleton [25]. Tenascin-C inhibits the contrac-
tion of the fibrin-fibronectin matrix implying a central
role for tenascin-C in the modulation of myofibroblast
contraction, which is important step in tissue repair
[26]. The role of tenascin-C in asthma in vivo is largely
unknown but aforementioned mechanisms shed some
light on the possible role of tenascin-C in remodelling.
In the present study, our OVA-challenged WT mice
showed enhanced expression of tenascin-C in the alveo-
lar structures and veins, whereas in the control mice,
tenascin-C was almost completely absent. Accordingly,
the expression of tenascin-C mRNA was higher in the
lungs of the OVA-challenged mice than in the control
mice. This is in accordance with the results of previous
studies that have also shown diminished allergic inflam-
mation in tenascin-C-negative mice [27].
In human adult bronchi, tenascin-C expression is
markedly higher in asthma patients in a stable phase
and even immediately after specific antigen challenge
[8,28,29]. The accumulation of tenascin-C is associated
with atopic but not with nonatopic asthma [9,30], and
the thickness of the tenascin-C layer correlates with
inflammatory cells in the lamina propria in atopic
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Figure 3 BAL cell counts and the airway hyperreactivity of STAT4-/- and STAT6-/- mice. A-B. Absolute numbers of eosinophils,
lymphocytes, macrophages and neutrophils in BAL fluid in STAT4-/- (A) and STAT6-/- (B) mice. C-D. Bronchial hyperreactivity of STAT4-/- (C) and
STAT6-/- (D) expressed as enhanced-pause values (Penh) for elevated concentrations of metacholine. RU = relative expression unit. Results are
expressed as mean ± SEM. *p < 0.05, ** p < 0.01, *** p < 0.001. n = 8 mice/group, except n = 9 mice/STAT4-/- OVA group.
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Page 6 of 9asthma [9]. In the ovalbumin-induced mouse allergy
model and in patients with atopic asthma, the Th2
type of inflammation prevails in the airways. Th1 cells,
IFN-g and TNF-a are considered important in severe
asthma [1,31]. No published studies have shown asso-
ciation between asthma severity and tenascin-C expres-
sion to our knowledge. To test whether Th1 or Th2
cells are important regulators of tenascin-C expression
in experimental allergic asthma, we studied the
responses of mice with impaired Th1 (STAT4-/-) or
Th2 (STAT6-/-) immunity. To our surprise, our results
revealed that tenascin-C expression was normal in
STAT6-deficient mice but severely impaired in
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Figure 4 Cytokine mRNA expression in the lungs of STAT4-/-
and STAT6-/- mice. The OVA-challenged STAT4-/- mice showed
significantly elevated expression of IL-4 in the lung tissue, but the
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OVA-challenged WT mice showed the most intensive expression
of tenascin-C, although no significant difference was found in
comparison with OVA-challenged STAT6-/- mice. In contrast,
STAT4-/- mice exhibited a lower intensity of tenascin-C
immunoreactivity than STAT6-/- and WT mice. 0 = no staining,
4 = very strong staining. n = 10 WT OVA; n = 9 WT PBS, STAT4-/-
O V A ;n=8S T A T 4 - / -P B S ,S T A T 6 - / -PBS, STAT6-/- OVA. Circles
represent the mean and the bars indicate the SEM. *p < 0.05,
**p < 0.01, *** p < 0.001.
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Page 7 of 9STAT4-deficient mice, thus suggesting that STAT4
plays a critical role in tenascin-C regulation. IFN-g and
TNF-a are known stimulators of tenascin-C expression
in bronchial epithelial cells [18], and at least TNF-a in
fibroblasts [19]. The low expression of tenascin-C in
our STAT4-/- mice may therefore be related to the
lack of IFN-g and TNF-a in these mice. This is also in
line with our in vitro results, which demonstrated that
the stimulation of cultured human MRC-9 fibroblasts
with recombinant TNF-a or with TNF-a and IFN-g
together from human primary fibroblasts induced the
expression of tenascin-C. Thus, the present results
suggest that proinflammatory cytokine TNF-a and Th1
cytokine IFN-g released into the airways after allergen
challenge critically regulate tenascin-C expression
and may therefore play an important role in initiating
the remodelling process of the airways. Our results,
together with previous studies that have shown
diminished expression of Th2 cytokines in tenascin-C-
negative mice [27], also support the role of tenascin-C
as possible mediator of inflammation.
Conclusions
We conclude that the first steps in the remodelling of
the airways are already evident in this mouse acute
allergic asthma model. After four weeks of challenge, we
found up-regulation of tenascin-C in the WT mice. The
STAT4-/- mice exhibited lower mRNA expression for
tenascin-C, TNF-a and IFN-g than did the WT mice.
This reinforces the role of STAT4 in allergic inflamma-
tion in addition to the rather well characterised role of
STAT6. The present results are consistent with those of
previous reports suggesting that the blocking of STAT6
m a ym a k ei tp o s s i b l et oi n h i b it allergen-induced AHR
responses and pulmonary eosinophilia. However, our
results also show that the expression of tenascin-C, a
possible early initiator of remodelling, is instead regu-
lated by the STAT4 transcription factor and TNF-a
with Th1 cytokine IFN-g in allergic airway inflammation.
M o r e o v e r ,t h i ss t u d y ,a sw e l la sp r e v i o u so n e s[ 3 2 , 3 3 ]
raises the question of the effectiveness of blocking only
the STAT6 pathway as a treatment for asthma. The role
of tenascin-C in the diagnosis and treatment of inflam-
matory airway diseases remains to be explored, but
tenascin-C may be a candidate for an early marker of
the remodelling process.
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